OBJECTIVE: To examine the predictors of antiretroviral adherence among HIV-infected adults, with a particular focus on advancing age, neuropsychological dysfunction, and substance abuse. DESIGN: : Prospective observational design. METHODS: Participants were 148 HIV-infected adults between the ages of 25 and 69 years, all on a self-administered antiretroviral regimen. Medication adherence was tracked over a one-month period using an electronic monitoring device (medication event monitoring system caps). All participants completed a comprehensive battery of neuropsychological tests as well as a structured psychiatric interview. RESULTS: The mean adherence rate for the entire cohort was 80.7%, with older patients (> or = 50 years) demonstrating significantly better medication adherence than younger patients (87.5 versus 78.3%). Logistic regression analyses found that older patients were three times more likely to be classified as good adherers (defined as > or = 95% adherent). Neurocognitive impairment conferred a 2.5 times greater risk of poor adherence. Among the older patients, those who were classified as poor adherers performed significantly worse on neuropsychological testing, particularly on measures of executive function and psychomotor speed. Current drug abuse/dependence, but not current alcohol abuse/dependence, was also associated with sub-optimal medication adherence. CONCLUSION: Although older age is associated with higher rates of antiretroviral adherence, older participants who were cognitively impaired showed disproportionate difficulty in adequately adhering to their medication regimen. As such, efforts to detect neuropsychological dysfunction, particularly among older patients, and a thorough assessment of substance abuse, appear to be essential for the effective treatment of HIV-infected adults.
OBJECTIVE: To examine the predictors of antiretroviral adherence among HIV-infected adults, with a particular focus on advancing age, neuropsychological dysfunction, and substance abuse. DESIGN: : Prospective observational design. METHODS:Participants were 148 HIV-infected adults between the ages of 25 and 69 years, all on a self-administered antiretroviral regimen. Medication adherence was tracked over a one-month period using an electronic monitoring device (medication event monitoring system caps). All participants completed a comprehensive battery of neuropsychological tests as well as a structured psychiatric interview. RESULTS: The mean adherence rate for the entire cohort was 80.7%, with older patients (> or = 50 years) demonstrating significantly better medication adherence than younger patients (87.5 versus 78.3%). Logistic regression analyses found that older patients were three times more likely to be classified as good adherers (defined as > or = 95% adherent). Neurocognitive impairment conferred a 2.5 times greater risk of poor adherence. Among the older patients, those who were classified as poor adherers performed significantly worse on neuropsychological testing, particularly on measures of executive function and psychomotor speed. Current drug abuse/dependence, but not current alcohol abuse/dependence, was also associated with sub-optimal medication adherence. CONCLUSION: Although older age is associated with higher rates of antiretroviral adherence, older participants who were cognitively impaired showed disproportionate difficulty in adequately adhering to their medication regimen. As such, efforts to detect neuropsychological dysfunction, particularly among older patients, and a thorough assessment of substance abuse, appear to be essential for the effective treatment of HIV-infected adults.
Authors: J Durant; P Clevenbergh; P Halfon; P Delgiudice; S Porsin; P Simonet; N Montagne; C A Boucher; J M Schapiro; P Dellamonica Journal: Lancet Date: 1999-06-26 Impact factor: 79.321
Authors: C C Carpenter; D A Cooper; M A Fischl; J M Gatell; B G Gazzard; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; M Schechter; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding Journal: JAMA Date: 2000-01-19 Impact factor: 56.272
Authors: D R Bangsberg; F M Hecht; E D Charlebois; A R Zolopa; M Holodniy; L Sheiner; J D Bamberger; M A Chesney; A Moss Journal: AIDS Date: 2000-03-10 Impact factor: 4.177
Authors: C H Hinkin; W G van Gorp; P Satz; T Marcotte; R S Durvasula; S Wood; L Campbell; M R Baluda Journal: J Clin Exp Neuropsychol Date: 1996-06 Impact factor: 2.475
Authors: David J Moore; Miguel Arce; Suzanne Moseley; J Allen McCutchan; Jennifer Marquie-Beck; Donald R Franklin; Florin Vaida; Cristian L Achim; Justin McArthur; Susan Morgello; David M Simpson; Benjamin B Gelman; Ann C Collier; Christina M Marra; David B Clifford; Robert K Heaton; Igor Grant Journal: J Neuropsychiatry Clin Neurosci Date: 2011 Impact factor: 2.198
Authors: Jordan E Cattie; Katie Doyle; Erica Weber; Igor Grant; Steven Paul Woods Journal: J Clin Exp Neuropsychol Date: 2012-06-25 Impact factor: 2.475
Authors: Mhairi Maskew; Alana T Brennan; A Patrick MacPhail; Ian M Sanne; Matthew P Fox Journal: J Int Assoc Physicians AIDS Care (Chic) Date: 2011-09-27
Authors: Caitlin N Pope; Jessica L Montoya; Elizabeth Vasquez; Josué Pérez-Santiago; Ronald Ellis; J Allen McCutchan; Dilip V Jeste; David J Moore; María J Marquine Journal: J Neurovirol Date: 2020-07-30 Impact factor: 2.643
Authors: Robert C Kalayjian; John Spritzler; Roy M Matining; Susan A Fiscus; Barry H Gross; Isaac R Francis; Richard B Pollard; Michael M Lederman; Alan Landay Journal: AIDS Date: 2013-06-19 Impact factor: 4.177